stemmacolore

Linea 4 – Ricerca clinica, traslazionale e terapie oncologica innovative

Linea 4 – Ricerca clinica, traslazionale e terapie oncologica innovative

RESPONSABILE

Dott.ssa Vittorina Zagonel

DESCRIZIONE

Elemento caratterizzante e prioritario della ricerca dello IOV è la conduzione di studi clinici innovativi, di medicina di precisione e traslazionali. Importanza cruciale per produrre conoscenze sul trattamento ottimale dei pazienti sono anche gli studi retrospettivi, osservazionali, traslazionali, interventistici rivolti sia all’ottimizzazione dei trattamenti già disponibili, sia allo sviluppo di terapie innovative, basate sulla caratterizzazione molecolare e sulla medicina di precisione. Altro elemento essenziale è la ricerca di fattori predittivi e prognostici e l’utilizzo dei patient reported outcomes (PROs) che valutino l’impatto di nuove terapie sulla qualità della vita dei pazienti.

BACKGROUND

Lo IOV si è contraddistinto per un continuo impegno nella promozione diretta e nell’adesione a protocolli clinici di ricerca farmacologica e non. I risultati ottenuti fino ad oggi hanno permesso di sviluppare e promuovere competenze all’avanguardia nell’ideazione, coordinamento e gestione di iniziative di ricerca clinica e traslazionale. La collaborazione con molte oncologie italiane garantisce un arruolamento competitivo in trials internazionali con farmaci innovativi. In ambito oncologico il rapido trasferimento al letto del malato di terapie innovative, garantisce a molti pazienti di beneficiare di nuove opportunità di cura in tempo reale. I risultati ottenuti devono essere misurati e monitorati con protocolli retrospettivi che sono una preziosa fonte di dati per ipotesi esplorative da verificare in maniera longitudinale. La ricerca clinica è punto di arrivo e di partenza di progetti traslazionali, ed è intimamente correlata alle altre linee di ricerca dello IOV.

RAZIONALE

La costante implementazione di nuove ricerche cliniche ha un valore strategico con immediate ricadute sul malato (sin dall’inserimento in studio), sull’esperienza dei singoli ricercatori e gruppi di ricerca (dal momento dell’ideazione), sulla comunità scientifica (alla presentazione e pubblicazione dei risultati). La ricerca clinica è connaturata alla mission di un IRCCS. Obiettivo strategico è implementare la ricerca traslazionale, e individuare indicatori predittivi di risposta per ottimizzare tipo e durata delle terapie innovative (es. Immunoterapia), al fine di garantire cure efficaci e socialmente sostenibili. Questi aspetti non possono prescindere da una visione a 360° del malato, in cui la prevenzione, riabilitazione, il ruolo infermieristico, psicologico, le terapie di supporto, nutrizionali, del dolore, e di qualità della vita, trovano giusta integrazione in programmi di ricerca disegnati con rigore metodologico come avviene per le sperimentazioni cliniche.

OBIETTIVI GLOBALI

  1. Progetti di ricerca in ogni snodo decisionale del percorso terapeutico-assistenziale: caratterizzazione molecolare delle neoplasie, ricerca traslazionale, personalizzazione delle cure, qualità della vita;
  2. espansione delle sperimentazioni non farmacologiche; analisi retrospettive e di outcome come monitoraggio e verifica dei risultati ottenuti.

RISULTATI ATTESI

  • Mantenimento e progressivo incremento del N. di studi clinici attivi.
  • Sviluppo e adesione a proposte di studio di ricerca indipendente, implementazione del coordinamento di iniziative nazionali e internazionali.
  • Promozione di studi traslazionali e di studi non farmacologici, orientati anche al rilievo di indicatori predittivi di risposta e utilizzo dei PROs come parametro di qualità della vita.
  • Diffusione dei risultati in ambito nazionale e internazionale.
  • Progressiva maggiore presenza e ruolo significativo del personale IOV all’interno di reti di collaborazione italiane ed internazionali (es. gruppi cooperatori, ACC, OECI, EORTC, etc).

Top 15 pubblicazioni 2021 linea 4
TitoloAutoriTestataIF grezzo
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell CarcinomaCheckMate 9ER Investigators Gruppo, Choueiri T. K., Powles T., Burotto M., Escudier B., Bourlon M. T., Zurawski B., Juárez V. M.Oyervides, Hsieh J. J., BASSO UMBERTO, Shah A. Y., Suárez C., Hamzaj A., Goh J. C., Barrios C., Richardet M., Porta C., Kowalyszyn R., Feregrino J. P., Zolnierek J., Pook D., Kessler E. R., Tomita Y., Mizuno R., Bedke J., Zhang J., Maurer M. A., Simsek B., Ejzykowicz F., Schwab G. M., Apolo A. B., Motzer R. J.NEW ENGLAND JOURNAL OF MEDICINE91.253
Immune checkpoint inhibitors in mesothelioma: a turning pointCeresoli Giovanni Luca, Pasello GiuliaLANCET79.323
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerJanjigian Yelena Y, Kawazoe Akihito, Yañez Patricio, Li Ning, Lonardi Sara, Kolesnik Oleksii, Barajas Olga, Bai Yuxian, Shen Lin, Tang Yong, Wyrwicz Lucjan S, Xu Jianming, Shitara Kohei, Qin Shukui, Van Cutsem Eric, Tabernero Josep, Li Lie, Shah Sukrut, Bhagia Pooja, Chung Hyun CheolNATURE49.962
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal CancerIveson Timothy J., Sobrero Alberto F., Yoshino Takayuki, Souglakos Ioannis, Ou Fang Shu, Meyers Jeffrey P., Shi Qian, Grothey Axel, Saunders Mark P., Labianca Roberto, Yamanaka Takeharu, Boukovinas Ioannis, Hollander Niels H., Galli Fabio, Yamazaki Kentaro, Georgoulias Vassilis, Kerr Rachel, Oki Eiji, Lonardi Sara, Harkin Andrea, Rosati Gerardo, Paul JamesJOURNAL OF CLINICAL ONCOLOGY44.544
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and OxaliplatinFontana Elisa, Meyers Jeff, Sobrero Alberto, Iveson Timothy, Shields Anthony F., Taieb Julien, Yoshino Takayuki, Souglakos Ioannis, Smyth Elizabeth C., Lordick Florian, Moehler Markus, Giraut Anne, Harkin Andrea, Labianca Roberto, Meyerhardt Jeffrey, André Thierry, Boukovinas Ioannis, Lonardi Sara, Saunders Mark, Vernerey Dewi, Oki Eiji, Georgoulias Vassilis, Ben-Aharon Irit, Shi QianJOURNAL OF CLINICAL ONCOLOGY44.544
Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON studyTabernero Josep, Grothey Axel, van Cutsem Eric, Yaeger Rona, Wasan Harpreet, Yoshino Takayuki, Desai Jayesh, Ciardiello Fortunato, Loupakis Fotios, Hong Yong Sang, Steeghs Neeltje, Guren Tormod Kyrre, Arkenau Hendrik Tobias, Garcia-Alfonso Pilar, Elez Elena, Gollerkeri Ashwin, Maharry Kati, Christy-Bittel Janna, Kopetz ScottJOURNAL OF CLINICAL ONCOLOGY44.544
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 StudyLenz Heinz-Josef, Van Cutsem Eric, Luisa Limon Maria, Wong Ka Yeung Mark, Hendlisz Alain, Aglietta Massimo, García-Alfonso Pilar, Neyns Bart, Luppi Gabriele, Cardin Dana B, Dragovich Tomislav, Shah Usman, Abdullaev Sandzhar, Gricar Joseph, Ledeine Jean-Marie, Overman Michael James, Lonardi SaraJOURNAL OF CLINICAL ONCOLOGY44.544
Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2- Negative Advanced Breast Cancer from SOLAR-1Ciruelos Eva Maria, Rugo Hope S., Mayer Ingrid A., Levy Christelle, Forget Frederic, Mingorance Juan Ignacio Delgado, Safra Tamar, Masuda Norikazu, Park Yeon Hee, Juric Dejan, Conte Pierfranco, Campone Mario, Loibl Sibylle, Iwata Hiroji, Zhou Xiaolei, Park Jinhee, Ridolfi Antonia, Lorenzo Ines, André FabriceJOURNAL OF CLINICAL ONCOLOGY44.544
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)Hecht J. Randolph, Lonardi Sara, Bendell Johanna, Sim Hao Wen, Macarulla Teresa, Lopez Charles D., Van Cutsem Eric, Muñoz Martin Andres J., Park Joon Oh, Greil Richard, Wang Hong, Hozak Rebecca R., Gueorguieva Ivelina, Lin Yong, Rao Sujata, Ryoo Baek YeolJOURNAL OF CLINICAL ONCOLOGY44.544
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana LinfomiMerli Francesco, Luminari Stefano, Tucci Alessandra, Arcari Annalisa, Rigacci Luigi, Hawkes Eliza, Chiattone Carlos S, Cavallo Federica, Cabras Giuseppina, Alvarez Isabel, Fabbri Alberto, Re Alessandro, Puccini Benedetta, Barraclough Allison, Delamain Marcia Torresan, Ferrero Simone, Usai Sara Veronica, Ferrari Angela, Cencini Emanuele, Pennese Elsa, Zilioli Vittorio Ruggero, Marino Dario, Balzarotti Monica, Cox Maria Christina, Zanni Manuela, Di Rocco Alice, Lleshi Arben, Botto Barbara, Hohaus Stefan, Merli Michele, Sartori Roberto, Gini Guido, Nassi Luca, Musuraca Gerardo, Tani Monica, Bottelli Chiara, Kovalchuk Sofia, Re Francesca, Flenghi Leonardo, Molinari Annalia, Tarantini Giuseppe, Chimienti Emanuela, Marcheselli Luigi, Mammi Caterina, Spina MicheleJOURNAL OF CLINICAL ONCOLOGY44.544
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialInvestigators MITO16b/MANGO¿OV2/ENGOT¿ov17, Pignata Sandro, Lorusso Domenica, Joly F., Gallo Ciro, Colombo N., Sessa Cristiana, Bamias Aristotelis, Salutari Vanda, Selle Frédèric, FREZZINI SIMONA, De Giorgi U., Pautier P., Bologna Alessandra, Orditura Michele, Dubot C., Gadducci Angiolo, Mammoliti S., Ray-Coquard I., Zafarana E., Breda Enrico, Favier L., Ardizzoia Antonio, Cinieri Saverio, Largillier R., Sambataro Daniela, Guardiola Emmanuel, Lauria R., Pisano C., Raspagliesi F., Scambia Giovanni, Daniele Gennaro, Perrone FrancescoLANCET ONCOLOGY41.316
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysisGroups MACH-NC and MARCH Collaborative, Petit Claire, Lacas Benjamin, Pignon Jean Pierre, Le Quynh Thu, Grégoire Vincent, Grau Cai, Hackshaw Allan, Zackrisson Björn, Parmar Mahesh K.B., Lee Ju Whei, Ghi Maria Grazia, Sanguineti Giuseppe, Temam Stéphane, Cheugoua-Zanetsie Maurice, O’Sullivan Brian, Posner Marshall R., Vokes Everett E., Cruz Hernandez Juan J., Szutkowski Zbigniew, Lartigau Eric, Budach V., Suwi¿ski Rafal, Poulsen Michael, Kumar Shaleen, Ghosh Laskar Sarbani, Mazeron Jean Jacques, Jeremic Branislav, Simes John, Zhong Lai Ping, Overgaard Jens, Fortpied Catherine, Torres-Saavedra Pedro, Bourhis Jean, Aupérin A., Blanchard P., Adelstein D. J., Agarwal J., Alfonsi M., Argiris A., Aupérin A., Bacigalupo A., Bar-Ad V., Bartelink H., Beadle B., Fallai C., Licitra L., Orecchia R., Torri V.LANCET ONCOLOGY41.316
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trialPinto C., Zucali P.A., Pagano M., Grosso F., Pasello Giulia, Garassino M.C., Tiseo M., Soto Parra H., Grossi F., Cappuzzo F., de Marinis F., Pedrazzoli P., Bonomi M., Gianoncelli L., Perrino M., Santoro A., Zanelli F., Bonelli C., Maconi A., Frega Stefano, Gervasi E., Boni L., Ceresoli G.L.LANCET ONCOLOGY41.316
HER2: a never ending storyDIECI MARIA VITTORIA, Miglietta FedericaLANCET ONCOLOGY41.316
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trialDESTINY-CRC01 investigators Gruppo, Siena Salvatore, Di Bartolomeo Maria, Raghav Kanwal, Masuishi Toshiki, Loupakis Fotios, Kawakami Hisato, Yamaguchi Kensei, Nishina Tomohiro, Fakih Marwan, Elez Elena, Rodriguez Javier, Ciardiello Fortunato, Komatsu Yoshito, Esaki Taito, Chung Ki, Wainberg Zev, Sartore-Bianchi Andrea, Saxena Kapil, Yamamoto Eriko, Bako Emarjola, Okuda Yasuyuki, Shahidi Javad, Grothey Axel, Yoshino TakayukiLANCET ONCOLOGY41.316

Fonte: Biblioteca scientifica IOV

Top 15 pubblicazioni Linea 4 anno 2020
TitoloAutori/AutriciRivistaIF grezzo
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationPrat Aleix, Guarneri Valentina, Paré Laia, Griguolo Gaia, Pascual Tomás, Dieci Maria Vittoria, Chic Núria, González-Farré Blanca, Frassoldati Antonio, Sanfeliu Esther, Cejalvo Juan M, Muñoz Montserrat, Bisagni Giancarlo, Brasó-Maristany Fara, Urso Loredana, Vidal Maria, Brandes Alba A, Adamo Barbara, Musolino Antonino, Miglietta Federica, Conte Benedetta, Oliveira Mafalda, Saura Cristina, Pernas Sònia, Alarcón Jesús, Llombart-Cussac Antonio, Cortés Javier, Manso Luis, López Rafael, Ciruelos Eva, Schettini Francesco, Villagrasa Patricia, Carey Lisa A, Perou Charles M, Piacentini Federico, D’Amico Roberto, Tagliafico Enrico, Parker Joel S, Conte PierfrancoLANCET ONCOLOGY33.752
A new standard of care for patients with high-risk rhabdomyosarcoma? – Authors’ replyBisogno Gianni, Ferrari Andrea, Melcon Soledad Gallego, De Salvo Gian Luca, Bergeron Christophe, Jenney MerielLANCET ONCOLOGY33.752
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092 STRASS): a multicentre, open-label, randomised, phase 3 trialBonvalot Sylvie, Gronchi Alessandro, Le Péchoux Cécile, Swallow Carol J., Strauss Dirk, Meeus Pierre, van Coevorden Frits, Stoldt Stephan, Stoeckle Eberhard, Rutkowski Piotr, Rastrelli Marco, Raut Chandrajit P., Hompes Daphne, De Paoli Antonino, Sangalli Claudia, Honoré Charles, Chung Peter, Miah Aisha, Blay Jean Yves, Fiore Marco, Stelmes Jean Jacques, Dei Tos Angelo P., Baldini Elizabeth H., Litière Saskia, Marreaud Sandrine, Gelderblom Hans, Haas Rick L.LANCET ONCOLOGY33.752
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialInvestigators GONO Foundation, Cremolini Chiara, Antoniotti Carlotta, Rossini Daniele, Lonardi Sara, Loupakis Fotios, Pietrantonio Filippo, Bordonaro Roberto, Latiano Tiziana Pia, Tamburini Emiliano, Santini Daniele, Passardi Alessandro, Marmorino Federica, Grande Roberta, Aprile Giuseppe, Zaniboni Alberto, Murgioni Sabina, Granetto Cristina, Buonadonna Angela, Moretto Roberto, Corallo Salvatore, Cordio Stefano, Antonuzzo Lorenzo, Tomasello Gianluca, Masi Gianluca, Ronzoni Monica, Di Donato Samantha, Carlomagno Chiara, Clavarezza Matteo, Ritorto Giuliana, Mambrini Andrea, Roselli Mario, Cupini Samantha, Mammoliti Serafina, Fenocchio Elisabetta, Corgna Enrichetta, zagonel vittorina, Boni Luca, Falcone Alfredo, De Braud Filippo Guglielmo Maria, Maiello Evaristo, Frassineti Giovanni Luca, Gianni Luca, Sobrero Alberto, Aglietta Massimo, Ballestrero Alberto, Silvestris Nicola, Tortora Giampaolo, Chiara Silvana, Brugnatelli Silvia, Banzi MariaLANCET ONCOLOGY33.752
Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)monarchE Committee Members and Investigators Gruppo, Johnston Stephen R.D., Harbeck Nadia, Hegg Roberto, Toi Masakazu, Martin Miguel, Shao Zhi Min, Zhang Qing Yuan, Rodriguez Jorge Luis Martinez, Campone Mario, Hamilton Erika, Sohn Joohyuk, Guarneri Valentina, Okada Morihito, Boyle Frances, Neven Patrick, Cortés Javier, Huober Jens, Wardley Andrew, Tolaney Sara M., Cicin Irfan, Smith Ian C., Frenzel Martin, Headley Desirée, Wei Ran, Antonio Belen San, Hulstijn Maarten, Cox Joanne, O’Shaughnessy Joyce, Rastogi PriyaJOURNAL OF CLINICAL ONCOLOGY32.956
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant TrialsCohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, Alberts S, Allegra C, de Gramont A, Seitz J-F, O’Connell M, Haller D, Wolmark N, Charles E, Zaniboni A, Lonardi Sara, Kerr R, Grothery A, Sinicrope F, Andrè T, Shi QJOURNAL OF CLINICAL ONCOLOGY32.956
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma GroupsGronchi Alessandro, Palmerini Emanuela, Quagliuolo Vittorio, Martin Broto Javier, Lopez Pousa Antonio, Grignani Giovanni, Brunello Antonella, Blay Jean-Yves, Tendero Oscar, Diaz Beveridge Robert, Ferraresi Virginia, Lugowska Iwona, Merlo Domenico Franco, Fontana Valeria, Marchesi Emanuela, Braglia Luca, Donati Davide Maria, Palassini Elena, Bianchi Giuseppe, Marrari Andrea, Morosi Carlo, Stacchiotti Silvia, Bagué Silvia, Coindre Jean Michel, Dei Tos Angelo Paolo, Picci Piero, Bruzzi Paolo, Casali Paolo GiovanniJOURNAL OF CLINICAL ONCOLOGY32.956
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100Moehler M, Dvorkin M, Boku N, Özgüro¿lu M, Ryu MH, Muntean AS, Lonardi Sara, Nechaeva M, Bragagnoli A, Co¿kun H, Gracian A, Takano T, Wong R, Safran H, Vaccaro GM, Wainberg ZA, Silver MR, Xiong H, Hong J, Taieb J, Bang Y-JJOURNAL OF CLINICAL ONCOLOGY32.956
Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trialVaidya Jayant S., Bulsara Max, Baum Michael, Wenz Frederik, Massarut Samuele, Pigorsch Steffi, Alvarado Michael, Douek Michael, Saunders Christobel, Flyger Henrik L., Eiermann Wolfgang, Brew-Graves Chris, Williams Norman R., Potyka Ingrid, Roberts Nicholas, Bernstein Marcelle, Brown Douglas, Sperk Elena, Laws Siobhan, Sütterlin Marc, Corica Tammy, Lundgren Steinar, Holmes Dennis, Vinante Lorenzo, Bozza Fernando, Pazos Montserrat, Le Blanc-Onfroy Magali, Gruber Günther, Polkowski Wojciech, Dedes Konstantin J., Niewald Marcus, Blohmer Jens, McCready David, Hoefer Richard, Kelemen Pond, Petralia Gloria, Falzon Mary, Joseph David J., Tobias Jeffrey S.BRITISH MEDICAL JOURNAL30.313
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical TrialPetrelli Fausto, Labianca Roberto, Zaniboni Alberto, Lonardi Sara, Galli Fabio, Rulli Eliana, Rosati Gerardo, Corallo Salvatore, Ronzoni Monica, Cardellino Giovanni Gerardo, Mattioli Rodolfo, Mambrini Andrea, Ciuffreda Libero, Banzi Maria, Pusceddu Valeria, Maiello Evaristo, Zampino Maria, zagonel vittorina, Marchetti Paolo, Corsi Domenico, Rimassa Lorenza, Cinieri Saverio, Sobrero AlbertoJAMA ONCOLOGY24.799
Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and LapatinibSartore-Bianchi Andrea, Lonardi Sara, Aglietta Massimo, Martino Cosimo, Ciardiello Fortunato, Marsoni Silvia, Siena SalvatoreJAMA ONCOLOGY24.799
Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results from the TARGIT-A Randomized Clinical Trial in Early Breast CancerVaidya Jayant S., Bulsara Max, Saunders Christobel, Flyger Henrik, Tobias Jeffrey S., Corica Tammy, Massarut Samuele, Wenz Frederik, Pigorsch Steffi, Alvarado Michael, Douek Michael, Eiermann Wolfgang, Brew-Graves Chris, Williams Norman, Potyka Ingrid, Roberts Nicholas, Bernstein Marcelle, Brown Douglas, Sperk Elena, Laws Siobhan, Sütterlin Marc, Lundgren Steinar, Holmes Dennis, Vinante Lorenzo, Bozza Fernando, Pazos Montserrat, Le Blanc-Onfroy Magali, Gruber Günther, Polkowski Wojciech, Dedes Konstantin J., Niewald Marcus, Blohmer Jens, McCready David, Hoefer Richard, Kelemen Pond, Petralia Gloria, Falzon Mary, Baum Michael, Joseph DavidJAMA ONCOLOGY24.799
Cobimetinib plus atezolizumab in BRAF(V600) wild-type melanoma: primary results from the randomized phase 3 IMspire170 studyGogas H, Dreno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Ferrucci F, Pigozzo Jacopo, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, Yan Y, Castro M, Mulla S, Flaherty K, Arance AANNALS OF ONCOLOGY18.274
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines CommitteeMichielin O., van Akkooi A., Lorigan P., Ascierto P. A., Dummer R., Robert C., Arance A., Blank C. U., chiarion sileni vanna, Donia M., Faries M. B., Gaudy-Marqueste C., Gogas H., Grob J. J., Guckenberger M., Haanen J., Hayes A. J., Hoeller C., Lebbé C., Lugowska I., Mandalà M., Márquez-Rodas I., Nathan P., Neyns B., Olofsson Bagge R., Puig S., Rutkowski P., Schilling B., Sondak V. K., Tawbi H., Testori A., Keilholz U.ANNALS OF ONCOLOGY18.274
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines CommitteeKeilholz U., Ascierto P. A., Dummer R., Robert C., Lorigan P., van Akkooi A., Arance A., Blank C. U., chiarion sileni vanna, Donia M., Faries M. B., Gaudy-Marqueste C., Gogas H., Grob J. J., Guckenberger M., Haanen J., Hayes A. J., Hoeller C., Lebbé C., Lugowska I., Mandalà M., Márquez-Rodas I., Nathan P., Neyns B., Olofsson Bagge R., Puig S., Rutkowski P., Schilling B., Sondak V. K., Tawbi H., Testori A., Michielin O.ANNALS OF ONCOLOGY18.274

Fonte: Biblioteca scientifica IOV

Top 15 pubblicazioni 2019 linea 4
TitoloAutoriRivistaIF grezzo
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal CancerKopetz Scott, Grothey Axel, Yaeger Rona, Van Cutsem Eric, Desai Jayesh, Yoshino Takayuki, Wasan Harpreet, Ciardiello Fortunato, Loupakis Fotios, Hong Yong Sang, Steeghs Neeltje, Guren Tormod K, Arkenau Hendrik-Tobias, Garcia-Alfonso Pilar, Pfeiffer Per, Orlov Sergey, Lonardi Sara, Elez Elena, Kim Tae-Won, Schellens Jan H M, Guo Christina, Krishnan Asha, Dekervel Jeroen, Morris Van, Calvo Ferrandiz Aitana, Tarpgaard L S, Braun Michael, Gollerkeri Ashwin, Keir Christopher, Maharry Kati, Pickard Michael, Christy-Bittel Janna, Anderson Lisa, Sandor Victor, Tabernero JosepNEW ENGLAND JOURNAL OF MEDICINE70.67
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic MelanomaRobert Caroline, Grob Jean J, Stroyakovskiy Daniil, Karaszewska Boguslawa, Hauschild Axel, Levchenko Evgeny, chiarion sileni vanna, Schachter Jacob, Garbe Claus, Bondarenko Igor, Gogas Helen, Mandalá Mario, Haanen John B A G, Lebbé Celeste, Mackiewicz Andrzej, Rutkowski Piotr, Nathan Paul D, Ribas Antoni, Davies Michael A, Flaherty Keith T, Burgess Paul, Tan Monique, Gasal Eduard, Voi Maurizio, Schadendorf Dirk, Long Georgina VNEW ENGLAND JOURNAL OF MEDICINE70.67
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaLarkin James, chiarion sileni vanna, Gonzalez Rene, Grob Jean-Jacques, Rutkowski Piotr, Lao Christopher D, Cowey C Lance, Schadendorf Dirk, Wagstaff John, Dummer Reinhard, Ferrucci Pier F, Smylie Michael, Hogg David, Hill Andrew, Márquez-Rodas Ivan, Haanen John, Guidoboni Massimo, Maio Michele, Schöffski Patrick, Carlino Matteo S, Lebbé Céleste, McArthur Grant, Ascierto Paolo A, Daniels Gregory A, Long Georgina V, Bastholt Lars, Rizzo Jasmine I, Balogh Agnes, Moshyk Andriy, Hodi F Stephen, Wolchok Jedd DNEW ENGLAND JOURNAL OF MEDICINE70.67
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trialBonvalot Sylvie, Rutkowski Piotr L., Thariat Juliette, Carrère Sébastien, Ducassou Anne, Sunyach Marie Pierre, Agoston P., Hong Angela, Mervoyer Augustin, Rastrelli Marco, Moreno Victor, Li Rubi K., Tiangco Béatrice, Herraez Antonio Casado, Gronchi Alessandro, Mangel László, Sy-Ortin Teresa, Hohenberger P., de Baère Thierry, Le Cesne Axel, Helfre Sylvie, Saada-Bouzid Esma, Borkowska A., Anghel Rodica, Co Ann, Gebhart Michael, Kantor Guy, Montero A., Loong Herbert H., Vergés Ramona, Lapeire Lore, Dema S., Kacso Gabriel, Austen Lyn, Moureau-Zabotto Laurence, Servois Vincent, Wardelmann Eva, Terrier Philippe, Lazar Alexander J., Bovée Judith V.M.G., Le Péchoux Cécile, Papai ZsusannaLANCET ONCOLOGY35.386
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialFuchs Charles S., Shitara Kohei, Di Bartolomeo Maria, Lonardi Sara, Al-Batran Salah Eddin, Van Cutsem Eric, Ilson David H., Alsina Maria, Chau Ian, Lacy Jill, Ducreux Michel, Mendez Guillermo Ariel, Alavez Alejandro Molina, Takahari Daisuke, Mansoor Wasat, Enzinger Peter C., Gorbounova Vera, Wainberg Zev A., Hegewisch-Becker Susanna, Ferry David, Lin Ji, Carlesi Roberto, Das Mayukh, Shah Manish A., Luft Alexander V., Karaseva Nina A., Kowalyszyn Rubén Dario, Hernandez Carlos Alberto, Csoszi Tibor, De Vita Ferdinando, Pfeiffer Per, Sugimoto Naotoshi, Kocsis Judit, Csilla Andràs, Bodoky Gyorgy, Garnica Jaliffe Georgina, Protsenko Svetlana, Madi Ayman, Wojcik Elzbieta, Brenner Baruch, Folprecht Gunnar, Sarosiek Tomasz, Peltola Katriina Johanna, Bono Peter, Ayala Hubert, Aprile Giuseppe, Gerardo Cardellino Giovanni, Huitzil Melendez Fidel David, Falcone Alfredo, Di Costanzo Francesco, Group RAINFALL StudyLANCET ONCOLOGY35.386
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialLebbé Celeste, Meyer Nicolas, Mortier Laurent, Marquez-Rodas Ivan, Robert Caroline, Rutkowski Piotr, Menzies Alexander M, Eigentler Thomas, Ascierto Paolo A, Smylie Michael, Schadendorf Dirk, Ajaz Mazhar, Svane Inge Marie, Gonzalez Rene, Rollin Linda, Lord-Bessen Jennifer, Saci Abdel, Grigoryeva Elena, Pigozzo JacopoJOURNAL OF CLINICAL ONCOLOGY28.349
Indeterminate Pulmonary Nodules at Diagnosis in Rhabdomyosarcoma: Are They Clinically Significant? A Report From the European Paediatric Soft Tissue Sarcoma Study GroupGroup on behalf of the EpSSG Radiology, Vaarwerk Bas, Bisogno Gianni, McHugh Kieran, Brisse Hervé J., Morosi Carlo, Corradini Nadège, Jenney Meriel, Orbach Daniel, Chisholm Julia C., Ferrari Andrea, Zanetti Ilaria, De Salvo Gian Luca, van Rijn Rick R., Merks Johannes H.M.JOURNAL OF CLINICAL ONCOLOGY28.349
Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 StudyDraaisma Kaspar, Chatzipli Aikaterini, Taphoorn Martin, Kerkhof Melissa, Weyerbrock Astrid, Sanson Marc, Hoeben Ann, Lukacova Slávka, Lombardi Giuseppe, Leenstra Sieger, Hanse Monique, Fleischeuer Ruth, Watts Colin, McAbee Joseph, Angelopoulos Nicos, Gorlia Thierry, Golfinopoulos Vassilis, Kros Johan M, Verhaak Roel G W, Bours Vincent, van den Bent Martin J, McDermott Ultan, Robe Pierre A, French Pim JJOURNAL OF CLINICAL ONCOLOGY28.349
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance TherapyMorano Federica, Corallo Salvatore, Lonardi Sara, Raimondi Alessandra, Cremolini Chiara, Rimassa Lorenza, Murialdo Roberto, Zaniboni Alberto, Sartore-Bianchi Andrea, Tomasello Gianluca, Racca Patrizia, Clavarezza Matteo, Adamo Vincenzo, Perrone Federica, Gloghini Annunziata, Tamborini Elena, Busico Adele, Martinetti Antonia, Palermo Federica, Loupakis Fotios, Milione Massimo, Fucà Giovanni, Di Bartolomeo Maria, de Braud Filippo, Pietrantonio FilippoJOURNAL OF CLINICAL ONCOLOGY28.349
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort ResultsSharma Padmanee, Siefker-Radtke Arlene, de Braud Filippo, Basso Umberto, Calvo Emiliano, Bono Petri, Morse Michael A, Ascierto Paolo A, Lopez-Martin Jose, Brossart Peter, Rohrberg Kristoffer, Mellado Begoña, Fischer Bruce S, Meadows-Shropshire Stephanie, Abdel Saci , Callahan Margaret K, Rosenberg JonathanJOURNAL OF CLINICAL ONCOLOGY28.349
Reply to E. Hindié and K.R. HessLong Georgina V, Dummer Reinhard, Schadendorf Dirk, Santinami Mario, Atkinson Victoria, Mandalà Mario, chiarion sileni vanna, Larkin James, Nyakas Marta, Dutriaux Caroline, Haydon Andrew, Robert Caroline, Mortier Laurent, Schachter Jacob, Lesimple Thierry, Plummer Ruth, Dasgupta Kohinoor, Haas Tomas, Shilkrut Mark, Gasal Eduard, Kefford Richard, Kirkwood John M, Hauschild AxelJOURNAL OF CLINICAL ONCOLOGY28.349
Quantitative evidence for early metastatic seeding in colorectal cancerHu Zheng, Ding Jie, Ma Zhicheng, Sun Ruping, Seoane Jose A, Scott Shaffer J, Suarez Carlos J, Berghoff Anna S, Cremolini Chiara, Falcone Alfredo, Loupakis Fotios, Birner Peter, Preusser Matthias, Lenz Heinz-Josef, Curtis ChristinaNATURE GENETICS25.455
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialPietrantonio Filippo, Morano Federica, Corallo Salvatore, Miceli Rosalba, Lonardi Sara, Raimondi Alessandra, Cremolini Chiara, Rimassa Lorenza, bergamo francesca, Sartore-Bianchi Andrea, Tampellini Marco, Racca Patrizia, Clavarezza Matteo, Berenato Rosa, Caporale Marta, Antista Maria, Niger Monica, Smiroldo Valeria, Murialdo Roberto, Zaniboni Alberto, Adamo Vincenzo, Tomasello Gianluca, Giordano Monica, Petrelli Fausto, Longarini Raffaella, Cinieri Saverio, Falcone Alfredo, zagonel vittorina, Di Bartolomeo Maria, de Braud FilippoJAMA Oncology22.416
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.Sledge George W, Toi Masakazu, Neven Patrick, Sohn Joohyuk, Inoue Kenichi, Pivot Xavier, Burdaeva Olga, Okera Meena, Masuda Norikazu, Kaufman Peter A, Koh Han, Grischke Eva-Maria, Conte Pierfranco, Lu Yi, Barriga Susana, Hurt Karla, Frenzel Martin, Johnston Stephen, Llombart-Cussac AntonioJAMA Oncology22.416
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studiesMarmorino F., Rossini D., Lonardi Sara, Moretto R., Zucchelli G., Aprile G., Dell’Aquila E., Ratti M., bergamo francesca, Masi G., Urbano F., Ronzoni M., Libertini M., Borelli B., Randon G., Buonadonna A., Allegrini G., Pella N., Ricci V., Boccaccino A., Latiano T. P., Cordio S., Passardi A., Tamburini E., Boni L., Falcone A., Cremolini C.ANNALS OF ONCOLOGY14.196

Fonte: Biblioteca scientifica IOV

Last modified: 22/07/2022 11:20

Torna su